HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Respiratory Synchronized Versus Intermittent Pneumatic Compression in Prevention of Venous Thromboembolism After Total Joint Arthroplasty: A Systematic Review and Meta-Analysis.

Abstract
The objective of this study was to evaluate the efficacy of respiratory synchronized compression devices (RSCDs) versus nonsynchronized intermittent pneumatic compression devices (NSIPCDs) in preventing venous thromboembolism (VTE) after total joint arthroplasty. A systematic literature review was conducted. Data regarding surgical procedure, deep vein thrombosis, pulmonary embolism, mortality, and adverse events were abstracted. Compared with control groups, the risk ratio of deep vein thrombosis development was 0.51 with NSIPCDs and 0.47 with RSCDs. This review demonstrates that RSCDs may be marginally more effective at preventing VTE events than NSIPCDs. Furthermore, the addition of mechanical prophylaxis to any chemoprophylactic regimen increases VTE prevention.
AuthorsAmeer M Elbuluk, Kelvin Y Kim, Kevin K Chen, Afshin A Anoushiravani, Ran Schwarzkopf, Richard Iorio
JournalThe Orthopedic clinics of North America (Orthop Clin North Am) Vol. 49 Issue 2 Pg. 123-133 (Apr 2018) ISSN: 1558-1373 [Electronic] United States
PMID29499814 (Publication Type: Comparative Study, Journal Article, Meta-Analysis, Review, Systematic Review)
CopyrightCopyright © 2017 Elsevier Inc. All rights reserved.
Chemical References
  • Fibrinolytic Agents
Topics
  • Arthroplasty, Replacement (adverse effects, methods)
  • Female
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Intermittent Pneumatic Compression Devices
  • Male
  • Observational Studies as Topic
  • Primary Prevention (methods)
  • Prognosis
  • Pulmonary Embolism (etiology, prevention & control)
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Treatment Outcome
  • United States
  • Venous Thromboembolism (etiology, prevention & control)
  • Venous Thrombosis (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: